Publications of William P. Petros, PharmD

Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs GR, Peer CJ, Petros WP.
Cancer Chemother Pharmacol. 2014;73(5):991-997.

PMC4010098.

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Hamadani M, Gibson LF, Remick SC, Wen S, Petros WP, Tse WW, Brundage KM, Vos JA, Cumpston AD, Bunner P, Craig M.
J Clin Oncol. 2013;31(35):4416-4423.

PMC3842909.

Duration of cisplatin excretion in breast milk.
Hays KE, Ryu RJ, Swisher EM, Reed E, McManus T, Rybeck B, Petros WP, Hebert MF.
J Hum Lact. 2013;29(4):469-472.

PMC4041270.

Three-dimensional hierarchical plasmonic nano-architecture enhanced surface-enhanced Raman scattering immunosensor for cancer biomarker detection in blood plasma.
Li M, Cushing SK, Zhang J, Suri S, Evans R, Petros WP, Gibson LF, Ma D, Liu Y, Wu NQ.
ACS Nano. 2013;7(6):4967-4976.

PMC3732798.

Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros WP, Mueller MD, Yu JJ.
Oncol Rep. 2012;27(1):286-292.


Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT((R))/leucovorin.
Peer CJ, McManus TJ, Hurwitz HI, Petros WP.
J Chromatogr B Analyt Technol Biomed Life Sci. 2012;898:32-37.


Effects of tobacco smoking and nicotine on cancer treatment.
Petros WP, Younis IR, Ford JN, Weed SA.
Pharmacotherapy. 2012;32(10):920-931.

PMC3499669.

Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts.
Rellick SL, Piktel D, Walton C, Hall B, Petros WP, Fortney JE, Gencheva M, Denvir J, Hobbs GR, Craig M, Gibson LF.
Cytokine. 2012;58(2):245-252.

PMC3319530.

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC.
Cancer Chemother Pharmacol. 2011;67(2):465-474.

PMC4086252.

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, Zhu Y, Statkevich P, Cutler DL, Hurwitz HI.
Cancer Chemother Pharmacol. 2011;67(2):455-463.


A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI.
Cancer Invest. 2011;29(9):617-625.

PMC4101887.

A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, Favaro J, Fernando NH, Morse MA, Blobe GC, Hurwitz HI.
Anticancer Res. 2010;30(4):1251-1256.

PMC4103189.

Meeting Report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010.
Lesinski GB, Carson WE, Repasky EA, Wei WZ, Kalinski P, Lotze MT, June CH, Petros WP, Muthusamy N, Olencki T.
J Immunother. 2010;33(7):659-662.

PMC3793645.

HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.
Yu JJ, Fu PF, Pink JJ, Dawson D, Wasman JK, Orem JN, Mwanda WO, Zhu HL, Liang XB, Guo Y, Petros WP, Mitsuyasu RT, Wabinga H, Remick SC.
PLoS One. 2010;5(5):e10477

PMC2871792.

Building a statewide clinical trials network for cancer care in West Virginia.
Abraham J, Keresztury J, Azar J, Monga M, Bowers T, Jones MP, Tirona MT, Pollock J, Coonley C, Jubelirer SJ, Frame J, Fogg P, Getto M, Filburn S, Naim JO, Lucas D, Petros WP, Hall S, Remick SC.
WV Med J. 2009;105 Spec No:6-11.


Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Dugan E, Truax R, Meadows KL, Blobe GC, Morse MA, Fernando NH, Gockerman JP, Petros WP, Hurwitz HI.
Anticancer Res. 2009;29(12):5149-5153.

PMC4103184.

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?
McMahon N, Cheng TY, Beasley GM, Spasojevic I, Petros WP, Augustine CK, Zipfel P, Padussis JC, Sanders G, Tyler DS.
Ann Surg Oncol. 2009;16(4):953-961.

PMC3872993.

Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
Younis IR, Malone S, Friedman HS, Schaaf LJ, Petros WP.
Cancer Chemother Pharmacol. 2009;63(3):517-524.

PMC3914774.

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros WP, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ.
Clin Cancer Res. 2008;14(19):6270-6276.


Metabolism of the cysteine S-conjugate of busulfan involves a {beta}-lyase reaction.
Cooper AJ, Younis IR, Niatsetskaya ZV, Krasnikov BF, Pinto JT, Petros WP, Callery PS.
Drub Metab Dispos. 2008;36:1546-1552.

PMC2587289.

A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Czito BG, Cohen DP, Kelsey CR, Lockhart AC, Bendell JC, Willett CG, Petros WP, D'Amico TA, Truax R, Hurwitz HI.
Int J Radiat Oncol Biol Phys. 2008;70(4):1066-1072.


Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Rao AV, Younis IR, Sand GJ, Spasojevic I, Adams DJ, DeCastro CM, Gockerman JP, Peterson BL, Petros WP, Moore JO, Rizzieri DA.
Leuk Lymphoma. 2008;49(8):1523-1529.


Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.
Younis IR, Elliott M, Peer CJ, Cooper AJ, Pinto JT, Konat GW, Kraszpulski M, Petros WP, Callery PS.
J Pharmacol Exp Ther. 2008;327(3):770-776.

PMC2678891.

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
Cancer Chemother Pharmacol. 2007;59(1):139-147.


Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM.
Clin Cancer Res. 2006;12(15):4636-4640.


A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
Czito BG, Hong TJ, Cohen DP, Petros WP, Tyler DS, Pappas TN, Yu D, Lee CG, Lockhart AC, Morse MA, Fernando NH, Hurwitz HI.
Cancer Invest. 2006;24(1):9-17.


Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM.
Clin Cancer Res. 2006;12(5):1540-1546.


Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors.
Hauck ML, LaRue SM, Petros WP, Poulson JM, Yu D, Spasojevic I, Pruitt AF, Klein A, Case B, Thrall DE, Needham D, Dewhirst MW.
Clin Cancer Res. 2006;12(13):4004-4010.


Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.
Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, Hussein AM, Rizzieri DA, Marks LB, Gilbert CJ, Affronti ML, Moore S, McDonald CS, Petros WP, Peters WP.
Biol Blood Marrow Transplant. 2006;12(2):195-203.


Phase I/II trial of intravenous doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
Alvarez SA, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW.
Int J Hyperthermia. 2005;21(4):333-347.


Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR.
J Clin Oncol. 2005;23(25):6117-6125.


A phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP, Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI.
Int J Radiat Oncol Biol Phys. 2004;58(3):779-785.


Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros WP, Garbriel D, Serody J, Kirby S, Wiley J.
Anticancer Drugs. 2004;15(5):453-459.


Pharmacogenomics in cancer therapy: is host genome variability important?
Petros WP, Evans WE.
Trends Pharmacol Sci. 2004;25(9):457-464.


Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
Cheng TY, Grubbs E, Abdul-Wahab O, Leu SY, Hung CF, Petros WP, Aloia T, Fedrau R, Pruitt S, Colvin M, Friedman HS, Tyler DS.
Am J Surg. 2003;186(5):460-467.


Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
Petros WP.
Pharmacotherapy. 2003;23(8 Pt 2):1S-2S.


Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ.
J Clin Oncol. 2003;21(23):4428-4438.


Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.
Bohjanen PR, Johnson MD, Szczech LA, Wray DW, Petros WP, Miller CR, Hicks CB.
Antimicrob Agents Chemother. 2002;46(8):2387-2392.

PMC127386.

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Dowlati A, Robertson K, Cooney MM, Petros WP, Stratford M, Jesberger JA, Rafie N, Overmoyer BA, Makkar V, Stambler BS, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC.
Cancer Res. 2002;62(12):3408-3416.


Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI.
Cancer Chemother Pharmacol. 2002;50(1):37-45.


Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Petros WP, Broadwater G, Berry DA, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP.
Clin Cancer Res. 2002;8(3):698-705.


Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer.
Rizvi NA, Marshall JL, Ness E, Hawkins MJ, Kessler C, Jacobs H, Brenckman WD, Jr., Lee JS, Petros WP, Hong WK, Kurie JM.
J Clin Oncol. 2002;20(16):3522-3532.


Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz HI, Moore JO.
J Clin Oncol. 2002;20(3):674-679.


Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM, Chiocca EA.
Cancer Res. 2001;61(3):864-868.


Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.
Bhalla KS, Wilczynski SW, Abushamaa AM, Petros WP, McDonald CS, Loftis JS, Chao NJ, Vredenburgh JJ, Folz RJ.
Am J Respir Crit Care Med. 2000;161(1):17-25.


Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW.
Cancer Res. 2000;60(24):6950-6957.


Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Ochoa L, Hurwitz HI, Wilding G, Cohen DP, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK.
Ann Oncol. 2000;11(10):1313-1322.


Phase I study of doxil and vinorelbine in metastatic breast cancer.
Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP.
Ann Oncol. 1999;10(9):1113-1116.


Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL.
J Clin Oncol. 1999;17(5):1516-1525.


Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.
Perry JJ, Fleming RA, Rocco MV, Petros WP, Bleyer AJ, Radford JE, Jr., Powell BL, Hurd DD.
Bone Marrow Transplant. 1999;23(8):839-842.


Metabolic jeopardy with high-dose cyclophosphamide?--not so fast.
Petros WP, Colvin OM.
Clin Cancer Res. 1999;5(4):723-724.


Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
Rizzieri DA, Vredenburgh JJ, Jones RB, Ross M, Shpall EJ, Hussein AM, Broadwater G, Berry DA, Petros WP, Gilbert CJ, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP.
J Clin Oncol. 1999;17(10):3064-3074.


Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.
Taylor CT, Petros WP, Ortel TL.
Pharmacotherapy. 1999;19(4):383-387.


Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.
Fisher DC, Vredenburgh JJ, Petros WP, Hussein AM, Berry DA, Elkordy M, Rubin P, Gilbert CJ, Peters WP.
Bone Marrow Transplant. 1998;21(2):117-122.


Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
Gilbert CJ, Petros WP, Vredenburgh JJ, Hussein AM, Ross M, Rubin P, Fehdrau R, Cavanaugh C, Berry DA, McKinstry C, Peters WP.
Cancer Chemother Pharmacol. 1998;42(6):497-503.


Effect of plasma TNF-alpha on filgrastim-stimulated hematopoiesis in mice and humans.
Petros WP, Rabinowitz J, Gibbs JP, Hall IH, Stuart AR, Peters WP.
Pharmacotherapy. 1998;18(4):816-823.


New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease.
Smith PF, Petros WP, Soucie MP, Copeland KR.
Ther Drug Monit. 1998;20(2):231-235.


The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer.
Vredenburgh JJ, Fishman R, Coniglio D, Matters L, Elkordy M, Ross M, Hussein AM, Rubin P, Gilbert CJ, Petros WP, Peters WP.
Am J Clin Oncol. 1998;21(6):543-547.


Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer.
Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ.
Am J Respir Crit Care Med. 1998;157(2):565-573.


A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M, Crump M, Vredenburgh JJ, Petros WP, Hussein AM, Rubin P, Ross M, Gilbert CJ, Modlin C, Meisenberg B, Coniglio D, Rabinowitz J, Laughlin MJ, Kurtzberg J, Peters WP.
Bone Marrow Transplant. 1997;19(4):315-322.


A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy.
Gattis WA, Petros WP, Pickard WW, Drew RH, May DB, Hathorn JW.
Pharmacotherapy. 1997;17(4):836-840.


Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.
Hare CB, Elion GB, Colvin OM, Ali-Osman F, Griffith OW, Petros WP, Keir S, Marcelli SL, Bigner DD, Friedman HS.
Cancer Chemother Pharmacol. 1997;40(5):409-414.


Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents.
Petros WP, Crawford J.
Curr Opin Hematol. 1997;4(3):213-216.


Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation.
Petros WP, Rabinowitz J, Stuart AR, Peters WP.
Clin Cancer Res. 1997;3(5):705-711.


Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.
Piscitelli SC, Reiss WG, Figg WD, Petros WP.
Clin Pharmacokinet. 1997;32(5):368-381.


Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.
Sutton LM, Warmuth MA, Petros WP, Winer EP.
Cancer Chemother Pharmacol. 1997;40(4):335-341.


The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ, Silva O, Broadwater G, Berry DA, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC, Jr.
Biol Blood Marrow Transplant. 1997;3(2):91-97.


Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer.
Fisher DC, Sherrill GB, Hussein AM, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros WP, Peters WP.
Bone Marrow Transplant. 1996;18(1):193-198.


A phase I/II study of high-dose cyclophosphamide, cisplatin, and thiotepa followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affronti ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert CJ, Gupton C, Egorin MJ, Soper JT, Berchuck A, Clarke-Pearson DL, Berry DA, Peters WP.
Cancer Chemother Pharmacol. 1996;37(6):561-568.


Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer.
Khawly JA, Rubin P, Petros WP, Peters WP, Jaffe GJ.
Ophthalmology. 1996;103(1):87-95.


The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline.
Petros WP, Rosner GL, Rabinowitz J, Gilbert CJ, Coniglio D, Vredenburgh JJ, Ross M, Peters WP.
Pharmacotherapy. 1996;16(5):742-748.


Carboplatin pharmacokinetics in young children with brain tumors.
Tonda ME, Heideman RL, Petros WP, Friedman HS, Murry DJ, Rodman JH.
Cancer Chemother Pharmacol. 1996;38(5):395-400.


Artifactual hypoglycemia associated with hematopoietic cytokines.
Astles JR, Petros WP, Peters WP, Sedor FA.
Arch Pathol Lab Med. 1995;119(8):713-716.


Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study.
Cartee L, Petros WP, Rosner GL, Gilbert CJ, Moore S, Affronti ML, Hoke JA, Hussein AM, Ross M, Rubin P.
Cytokine. 1995;7(5):471-477.


Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Hussein AM, Ross M, Vredenburgh JJ, Meisenberg B, Hars V, Gilbert CJ, Petros WP, Coniglio D, Kurtzberg J, Rubin P.
Eur J Haematol. 1995;55(5):348-356.


Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.
Kurpad SN, Friedman HS, Archer GE, McLendon RE, Petros WP, Fuchs HE, Guaspari A, Bigner DD.
Cancer Res. 1995;55(17):3803-3809.


Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity.
Murase T, Anscher MS, Petros WP, Peters WP, Jirtle RL.
Bone Marrow Transplant. 1995;15(2):173-178.


Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantation.
Petros WP, Rabinowitz J, Stuart AR, Gupton C, Alderman EM, Peters WP.
Exp Hematol. 1994;22(7):582-586.


Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.
Petros WP, Chaney SG, Smith DC, Fangmeier J, Sakata M, Brown TD, Trump DL.
Cancer Chemother Pharmacol. 1994;33(4):347-354.


Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.
Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL.
N Engl J Med. 1993;328(22):1592-1598.


High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways.
Karolak L, Chandra A, Khan W, Marks B, Petros WP, Peters WP, Greenberg CS, Hannun YA.
Mol Pharmacol. 1993;43(1):37-44.


Role of cytokines in autologous bone marrow transplantation.
Peters WP, Ross M, Vredenburgh JJ, Hussein AM, Meisenberg B, Gilbert CJ, Petros WP, Kurtzberg J.
Hematol Oncol Clin North Am. 1993;7(3):737-747.


High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer EP, Kurtzberg J, Bast RC, Jr., Jones RB, Shpall EJ, Wu K, Rosner GL, Gilbert CJ, Mathias B, Coniglio D, Petros WP, Henderson C, Norton L, Weiss R, Hurd DD.
J Clin Oncol. 1993;11(6):1132-1143.


Hematopoietic colony-stimulating factors and dose intensity.
Petros WP, Peters WP.
Semin Oncol. 1993;20(1):94-99.


Cost implications of haematopoietic growth factors in the BMT setting.
Petros WP, Peters WP.
Bone Marrow Transplant. 1993;11 Suppl 2:36-38.


Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support.
Rabinowitz J, Petros WP, Stuart AR, Peters WP.
Blood. 1993;81(9):2452-2459.


Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui CH, Rivera GK.
J Pharmacol Exp Ther. 1992;260(1):71-77.


Pharmacokinetics and administration of colony-stimulating factors.
Petros WP.
Pharmacotherapy. 1992;12(2 Pt 2):32S-38S.


Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support.
Petros WP, Rabinowitz J, Stuart AR, Gilbert CJ, Kanakura Y, Griffin JD, Peters WP.
Blood. 1992;80(5):1135-1140.


Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.
Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, Evans WE.
Pharmacotherapy. 1992;12(4):273-277.


Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.
Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM.
J Clin Oncol. 1991;9(6):1022-1028.


Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.
Petros WP, Rodman JH, Mirro J, Jr., Evans WE.
Cancer Chemother Pharmacol. 1991;27(5):397-400.


Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.
Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE.
Clin Pharmacol Ther. 1991;50(3):308-313.


Pharmacokinetics and pharmacodynamics of anticancer agents: contributions to the therapy of childhood cancer.
Petros WP, Evans WE.
Pharmacotherapy. 1990;10(5):313-325.


Clinical pharmacology of cancer chemotherapy in children.
Evans WE, Petros WP, Relling MV, Crom WR, Madden T, Rodman JH, Sunderland M.
Pediatr Clin North Am. 1989;36(5):1199-1230.


Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.
Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Jr., Crom WR.
Clin Pharmacol Ther. 1989;45(5):568-573.


A standardized parenteral nutrition solution: prescribing, use, processing, and material cost implications.
Petros WP, Shank WA, Jr.
Hosp Pharm. 1986;21(7):648-6.